Nonetheless, our findings suggest that connected pens such as the NovoPen® 6 have the potential to improve glycemic control, decrease glucose variability and increase treatment concordance in people with T1D, addressing the large unmet need for optimal insulin treatment. This evidence concerns the gene INS and type 1 diabetes mellitus.